分析家对人工生化治疗的多重“Buy”评级,目标价格在18至23美元之间。 Artiva Biotherapeutics receives multiple "Buy" ratings from analysts with target prices between $18-$23.
临床阶段生物技术公司Artiva Biotherapeutics (NASDAQ:ARTV) 开发天然杀手 (NK) 细胞疗法,用于自身免疫性疾病和癌症,该公司已获得包括Nedham & Company在内的分析师的多次"购买"评级,该公司设定了23美元的目标价格. Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech firm developing natural killer (NK) cell therapies for autoimmune diseases and cancers, has received multiple "Buy" ratings from analysts, including Needham & Company, which set a target price of $23.00. Wedbush、TD Cowen和Jefferies等其他公司也发放了购买评级,目标在18美元至23美元之间。 Other firms like Wedbush, TD Cowen, and Jefferies also issued buy ratings with targets between $18.00 and $23.00. 该公司的主要候选人AB-101的目标是若干严重条件。 The company's lead candidate, AB-101, targets several serious conditions.